Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Cymbalta's Expanded GAD Claim Is A Load Off Lilly's Mind
Approval for maintenance treatment of generalized anxiety disorder may be more about shoring up the blockbuster drug than creating a market for growth.
Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor
Patients treated with Cymbalta show greater reduction in pain compared to placebo in a six-month pivotal trial, Lilly reports.
Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor
Patients treated with Cymbalta show greater reduction in pain compared to placebo in a six-month pivotal trial, Lilly reports.